Disease State Overview
- There are approximately 5,690 patients in the US diagnosed with Acute Lymphoblastic Leukemia (ALL) per year1
- It is estimated that 10-15% of these ALL patients have T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL )1
- The majority of these patients are children under 5 years of age.
Shorla Oncology have submitted, and the US Food and Drug Administration (‘FDA’) have accepted for filing, its application for its SH-111 oncology drug designed to treat T-cell leukemia. SH-111 is a life changing treatment that is often in shortage and the company looks forward to working closely with FDA to bring this much needed product to market in 2022.
1 American Cancer Society. Cancer Facts & Figures, 2021.